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Background
Merkel cell carcinoma (MCC) of the skin is a highly malig-
nant primary cutaneous neuroendocrine malignancy.
Older individuals, patients undergoing immunosuppres-
sive therapy for organ transplant, and patients with HIV
infection who are immunosuppressed are at a higher risk
for developing MCC. MCC may share etiologic influences
with other malignancies, and increased risks for other can-
cers in MCC patients have been reported. Feng et al
recently identified a new human polyoma virus, Merkel
Cell Virus (MCV), in MCC. The discovery of MCV raises
important questions. Is MCV obligatory for MCC? The
absence of the viral genome in 20 percent of the 10 MCC
cases in the index study suggests that some MCC may not
be associated with MCV. What is the natural reservoir for
this virus? Feng et al demonstrated low levels of detection
in skin samples from non-disease controls. How prevalent
is an MCV latent or active infection? Can detection be car-
ried out in archived formalin fixed paraffin embedded
(FFPE) tissue samples of MCC to clarify the association
between MCV and MCC? Until such time as tools for
serology are available polymerase chain reaction (PCR)
based detection methods, particularly those that can effec-
tively be applied to small and FFPE samples, will be valu-
able.
Methods
A real time PCR assay for MCV was developed using a
known source of fresh, frozen MCC with confirmed inte-
grated MCV kindly provided by Dr. Patrick Moore, Uni-
versity of Pittsburgh. The assay readily and reproducibly
amplified MCV DNA. To test the assay in FFPE tissues, we
assembled a 25-case series of primary and metastatic MCC
archived from 1994 to 2008. A tissue microarray (TMA)
was constructed to confirm the MCC diagnosis by a bat-
tery of immunohistochemistry tests. These 25 FFPE sam-
ples included MCC from 22 individual patients some with
and some without known immunodeficiency. Duplicate
diagnostic blocks were available from nine patients. The
PCR samples were coded off site so the identity and inter-
relationships of the samples were unavailable to persons
performing the PCR assay. In addition to reagent controls,
we included DNA from 12 colon carcinomas and 20
breast carcinomas.
Results
The MCV real-time PCR assay had excellent linearity with
an input of genomic DNA in the range of 10 ng to 0.1 ng
corresponding to 1000 to 10 cells. With 40 cycles of
amplification, DNA from peripheral blood lymphocytes
(PBL) used as a negative control reproducibly scored neg-
ative for amplification of MCV. This assay readily and
reproducibly amplified MCV DNA from the known source
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of MCV in fresh, frozen MCC. We demonstrated that this
PCR assay could detect MCV in as few as 10 cells. No DNA
controls and PBL samples used as negative controls
yielded a Ct of 40 as expected. The Ct values for the con-
firmed MCC FFPE samples ranged from 18 to 40, with a
mean value of 31, demonstrating heterogeneity in the
association of MCV with MCC. PCR assay was readily able
to amplify MCV independent of the age of the MCC tis-
sues. All duplicate MCC tissues showed strong concord-
ance in detection. Level of MCV DNA associated in
duplicate biopsies was tightly concordant in six of nine.
Diagnostic tissue from one patient included three inde-
pendent sites, biopsied at different time points in the
course of the disease. MCV was detected in two of these
biopsies but the third axillary metastatic MCC tissue was
negative. An inverse correlation was suggested between
patient survival and the level of MCV DNA observed. MCV
DNA was not detected in nine colon cancer tissues, but a
low level (Ct 38) of MCV DNA was reproducibly detected
in three of 20 breast cancers.
Conclusion
We have developed and validated a PCR assay to reliably
detect and quantify MCV DNA from archived FFPE tis-
sues. Using this newly developed real time PCR assay, we
confirmed the association of MCV with MCC and demon-
strated heterogeneity of MCV association with MCC. Fur-
thermore, this PCR assay suggests that MCV can be
detected in DNA from tissues other than MCC and thus
might be useful in assessing the prevalence of MCV in var-
ious malignancies and body sites. Much remains to be
done, including investigation of 1) correlations of MCV
positivity in MCC with other biomarkers and 2) the pos-
sibility that MCC tissues demonstrate immunohisto-
chemical cross-reactivity with available polyoma T virus
reagents, both of which are in progress.Page 2 of 2
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